- Home
- DRMA vs XWEL Comparison
DRMA vs XWEL Comparison
Compare DRMA & XWEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRMA
- XWEL
- Stock Information
- Founded
- DRMA 2014
- XWEL 2006
- Country
- DRMA United States
- XWEL United States
- Employees
- DRMA N/A
- XWEL N/A
- Industry
- DRMA Biotechnology: Pharmaceutical Preparations
- XWEL Other Consumer Services
- Sector
- DRMA Health Care
- XWEL Consumer Discretionary
- Exchange
- DRMA Nasdaq
- XWEL Nasdaq
- Market Cap
- DRMA 4.5M
- XWEL 4.7M
- IPO Year
- DRMA 2021
- XWEL N/A
- Fundamental
- Price
- DRMA $0.71
- XWEL $0.98
- Analyst Decision
- DRMA Strong Buy
- XWEL
- Analyst Count
- DRMA 1
- XWEL 0
- Target Price
- DRMA $3.00
- XWEL N/A
- AVG Volume (30 Days)
- DRMA 118.5K
- XWEL 47.3K
- Earning Date
- DRMA 08-06-2025
- XWEL 08-13-2025
- Dividend Yield
- DRMA N/A
- XWEL N/A
- EPS Growth
- DRMA N/A
- XWEL N/A
- EPS
- DRMA N/A
- XWEL N/A
- Revenue
- DRMA N/A
- XWEL $32,194,000.00
- Revenue This Year
- DRMA N/A
- XWEL N/A
- Revenue Next Year
- DRMA N/A
- XWEL N/A
- P/E Ratio
- DRMA N/A
- XWEL N/A
- Revenue Growth
- DRMA N/A
- XWEL 1.33
- 52 Week Low
- DRMA $0.57
- XWEL $0.70
- 52 Week High
- DRMA $5.00
- XWEL $2.70
- Technical
- Relative Strength Index (RSI)
- DRMA 53.74
- XWEL 54.46
- Support Level
- DRMA $0.61
- XWEL $0.90
- Resistance Level
- DRMA $0.74
- XWEL $1.05
- Average True Range (ATR)
- DRMA 0.06
- XWEL 0.08
- MACD
- DRMA 0.01
- XWEL 0.00
- Stochastic Oscillator
- DRMA 67.43
- XWEL 50.00
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.
About XWEL XWELL Inc.
XWELL Inc is a health and wellness holding company. It is an airport retailer of spa services through XpresSpa locations, offering travelers premium spa services, including massage, nail, and skincare, as well as spa and travel products. It operates four reportable operating segments: XpresSpa. XpresTest, Naples Wax Center and Treat. XpresSpa provides travelers with premium spa services, including massage, nail and skin care, as well as spa and travel products. Treat is a travel health and wellness brand that offers in-airport spa. XpresTest provides COVID-19 screening and diagnostic testing in partnership with the CDC. Naples Wax Center operates three high-performing locations with core products and service offerings from face and body waxing to a range of skincare and cosmetic products.